• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Eli Lilly (NY:LLY)

    1,023.80 -15.71 (-1.51%)
    Official Closing Price Updated: 4:10 PM EST, Jan 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Eli Lilly

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    FDA Codifies AI’s Role in Drug Production: New 2026 Guidelines Set Global Standard for Pharma Safety and Efficiency
    In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial... 
    Via TokenRing AI
    Topics Artificial Intelligence Economy
    News headline image
    The Biological Singularity: How Nobel-Winning AlphaFold 3 is Rewriting the Blueprint of Life
    In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic... 
    Via TokenRing AI
    Topics Artificial Intelligence Economy
    Eli Lilly & Co (NYSE:LLY) Presents a Compelling Mix of Fundamental Growth and Technical Breakout Potential ↗
    Via Chartmill
    Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week ↗
    Via Stocktwits
    News headline image
    Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences
    In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire... 
    Via MarketMinute
    News headline image
    Eli Lilly Strikes $1.1 Billion Deal With Seamless Therapeutics To Develop Gene Therapies For Hearing Loss ↗
    Under the terms of the deal between Seamless Therapeutics and Eli Lilly, Seamless will design and program site-specific enzymes to correct mutations in certain genes related to hearing loss. 
    Via Stocktwits
    Topics Economy Government
    News headline image
    Top Picks 2026: Eli Lilly & Co. ↗
    LLY is surging as its weight-loss duopoly remains a 2026 
    Via Talk Markets
    News headline image
    The Master Architect of Molecules: How Google DeepMind’s AlphaProteo is Rewriting the Blueprint for Cancer Therapy
    In the quest to cure humanity’s most devastating diseases, the bottleneck has long been the "wet lab"—the arduous, years-long process of trial and error required to find a protein that can stick to a... 
    Via TokenRing AI
    Topics Artificial Intelligence
    News headline image
    Eli Lilly Reinforces Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
    In a decisive move to solidify its leadership in the next generation of chronic inflammation and cardiometabolic treatments, Eli Lilly and Company (NYSE: LLY) announced the acquisition of Ventyx... 
    Via MarketMinute
    News headline image
    1 Pharmaceutical Stock Set to Rebound in 2026 ↗
    Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026. 
    Via The Motley Fool
    News headline image
    Carvina Capital: Strong Demand Lifts Aktis IPO
    Via AB Newswire
    News headline image
    Up 36%, Is Eli Lilly Still a Buy? ↗
    Thanks to its weight loss and diabetes products, the drug company has seen its shares soar. 
    Via The Motley Fool
    News headline image
    Where Will Eli Lilly Be in 10 Years? ↗
    Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever. 
    Via The Motley Fool
    Topics ETFs Intellectual Property
    News headline image
    2 Profitable Stocks to Own for Decades and 1 Facing Headwinds
    Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
    Via StockStory
    News headline image
    A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack
    The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Ocular Therapeutix... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    The Silicon Laureates: How the 2024 Nobel Prizes Rewrote the Rules of Scientific Discovery
    The year 2024 marked a historic inflection point in the history of science, as the Royal Swedish Academy of Sciences awarded Nobel Prizes in both Physics and Chemistry to pioneers of artificial... 
    Via TokenRing AI
    Topics Artificial Intelligence
    News headline image
    Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? ↗
    Both companies may succeed in this industry. 
    Via The Motley Fool
    News headline image
    A Look Into Eli Lilly and Co Inc&#39;s Price Over Earnings ↗
     
    Via Benzinga
    News headline image
    The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
    The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market... 
    Via Finterra
    Topics Economy Initial Public Offering
    News headline image
    Prediction: This Healthcare Stock Could Soar by 40% in 2026 ↗
    This pharmaceutical giant has recently caught fire, and the stock's run is likely just beginning. 
    Via The Motley Fool
    News headline image
    My Top AI Healthcare Stock to Buy and Hold for 20 Years ↗
    This drugmaker continues to strengthen its investment thesis. 
    Via The Motley Fool
    Topics Artificial Intelligence Intellectual Property
    News headline image
    3 Mid-Cap Stocks with Open Questions
    Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
    Via StockStory
    News headline image
    3 Growth Stocks to Invest $1,000 in Right Now ↗
    It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Should You Dump Eli Lilly's Shares After This Setback? ↗
    The company got some bad news to start 2026. 
    Via The Motley Fool
    News headline image
    Google, Nvidia, Lilly Lead 5 Stocks Near Buy Points ↗
    These trillion-dollar stocks may be setting up for their next move. 
    Via Investor's Business Daily
    News headline image
    The $5 Trillion Renaissance: How 2025 Redefined Global Deal-Making
    The global financial landscape has undergone a seismic shift as 2025 closed with merger and acquisition (M&A) volumes surpassing a staggering $5 trillion. This "M&A Renaissance" marks a definitive end... 
    Via MarketMinute
    Topics Artificial Intelligence Economy
    News headline image
    Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
    Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing. 
    Via The Motley Fool
    News headline image
    Why a 15% Dividend Wasn’t Enough to Keep This $3.3 Million Position ↗
    Trinity Capital provides venture debt and equipment financing to growth-stage tech companies seeking non-dilutive capital solutions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Outfront Media Surges 40% in One Year, Then Gets Cut Loose Despite 'Exceptional Performance' ↗
    This out-of-home advertising REIT connects brands with urban audiences through a broad network of billboard and transit assets. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly
    Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of... 
    Via Finterra
    Topics Intellectual Property
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.